Changes of doxorubicin distribution in blood and plasma after its inclusion into nanophospholipid formulations

Biochemistry (Moscow) Supplement Series B: Biomedical Chemistry

Volumn 6, Issue 1, 2012, Pages 39-41

  Zykova, M G ^a   Ipatova, O M ^a   Prozorovskii, V N ^a   Medvedeva, N V ^a   Voskresenskaya, A A ^a   Zakharova, T S ^a   Torkhovskaya, T I ^a  

^a INSTITUTE OF BIOMEDICAL CHEMISTRY   (Russian Federation)

Author keywords

doxorubicin; erythrocytes; lipoproteins; phospholipids nanoparticles

Indexed keywords

DOXORUBICIN; HIGH DENSITY LIPOPROTEIN; NANOPARTICLE; PHOSPHOLIPID;

ANIMAL CELL; ARTICLE; BLOOD CELL; CELL ADHESION; CONTROLLED STUDY; DRUG BINDING; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG PROTEIN BINDING; IN VITRO STUDY; MALE; NANOPHARMACEUTICS; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; PROCESS DEVELOPMENT; RAT;

EID: 84857932801     PISSN: 19907508     EISSN: 19907516     Source Type: Journal    
DOI: 10.1134/S1990750812010155     Document Type: Article

References (15)

1. Hammer, E., Bien, S., Salazar, M.G., Steil, L., Scharf, C., Hildebrandt, P., Schroeder, H.W., Kroemer, H.K., Völker, U., and Ritter, C.A., Proteomics, 2010, vol. 10, pp. 99-114.
2. Cowens, J.W., Creaven, P.J., Greco, W.R., Brenner, D.E., Tung, Y., Ostro, M., Pilkiewicz, F., Ginsberg, R., and Petrelli, N., Cancer Res., 1993, vol. 53, pp. 2796-2802.
3. Pérez-López, M.E., Curiel, T., Gómez, J.G., and Jorge, M., Anticancer Drugs, 2007, vol. 18, pp. 611-617.
4. Ipatova, O.M., Zykova, M.G., Torkhovskaya, T.I., Medvedeva, N.V., and Prozorovskii, V.N., Biomed. Khim., 2009, vol. 55, pp. 185-194.
5. Archakov, A.I., Ipatova, O.M., Medvedeva, N.V., Prozorovskii, V.N., Torkhovskaya, T.I., Tikhonova, E.G., Zykova, M.G., and Voskresenskaya, A.A., RF Patent application no. 2009131864/044633 of 25.08.2009.
6. Gabano, E., Ravera, M., and Osella, D., Curr. Med. Chem., 2009, vol. 16, pp. 4544-4580.
7. Vaijayanthimala, V., Tzeng, Y.K., Chang, H.C., and Li, C.L., Nanotechnology, 2009, vol. 20, pp. 425103.
8. Wasan, K.M., Brocks, D.R., Lee, S.D., Sachs-Barrable, K., and Thornton, S.J., Nat. Rev. Drug Discov., 2008, vol. 7, pp. 84-99.
9. Tertov, V.V., Angiol. Sos. Khir., 1999, vol. 5 (Suppl.), pp. 218-239.
10. Marczak, A., Kowalczyk, A., Wrzesień-Kus, A., Robak, T., Jóźwiak, Z., Cell Biol. Int., 2006, vol. 30, pp. 127-132.
11. Khan, S.N. and Khan, A.U., Bioinformation, 2008, vol. 2, pp. 401-404.
12. Laginha, K.M., Verwoert, S., Charrois, G.J., and Allen, T.M., Clin. Cancer Res., 2005, vol. 11(19, pt 1), pp. 6944-6949.
13. Menrad, A. and Anderer, F.A., Anticancer Res., 1991, vol. 11, pp. 385-390.
14. McConathy, W.J., Nair, M.P., Paranjape, S., Mooberry, L., and Lacko, A.G., Anticancer Drugs, 2008, vol. 19, pp. 183-188.
15. Kwong, M. and Wasan, K.M., Biochem. Pharmacol., 2002, vol. 64, pp. 1669-1675.